A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen).
Binding of iodine-125-labeled thrombin to fibrin clots from two siblings with juvenile stroke was 30% of normal, and abnormally high amounts of the radioligand (not adsorbed by fibrin) were found in the supernatant. In concordance with this finding, supernatants from the patients' fibrin clots caused abnormal enhancement of platelet aggregation, ATP secretion, and binding of 125I-fibrinogen to platelets exposed to subthreshold concentrations of ADP or epinephrine. Hirudin suppressed the enhancing effect of the patients' supernatants, and substitution of gamma-thrombin for alpha-thrombin led to normalization of platelet responses. Under some experimental conditions, degradation of the patients' fibrinogen by plasmin was impaired. However, the euglobulin lysis time, the rate of fibrin degradation by plasmin, and the lysis of the patients' plasma clots by human melanoma tissue-type plasminogen activator were normal. Patients' plasmas, as well as purified fibrinogen, showed a prolonged thrombin time (partially corrected by 10 mM CaCl2) and an impaired release of fibrinopeptide A in response to thrombin. However, the release in response to reptilase was normal, and the reptilase, ancrod, and thrombin coagulase times were within control (normal) values. In addition, the patients' fibrinogen showed normal polymerization of preformed fibrin monomers, normal sialic acid content, and normal binding to ADP or epinephrine-stimulated platelets. Our studies support the concept that thrombin and platelets play an important role in the occurrence of stroke in these patients and suggest a direction to be followed to identify the mechanism(s) contributing to thrombosis in subjects with abnormal fibrinopeptide release.
Di Minno
G
G
Istituto di Medicina Interna e Malattie Dismetaboliche, Università degli Studi di Napoli, Italy.
Martinez
J
J
Cirillo
F
F
Cerbone
A M
AM
Silver
M J
MJ
Colucci
M
M
Margaglione
M
M
Tauro
R
R
Semeraro
N
N
Quattrone
A
A
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D001777:Blood Coagulation / Q000502:physiology; D001792:Blood Platelets / Q000378:metabolism / Q000502:physiology*; D002561:Cerebrovascular Disorders / Q000097:blood*; D004591:Electrophoresis, Polyacrylamide Gel; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D005337:Fibrin / Q000378:metabolism; D015241:Fibrinogens, Abnormal / Q000378:metabolism*; D005341:Fibrinolysin / Q000378:metabolism; D005344:Fibrinopeptide A / Q000378:metabolism; D006629:Hirudins / Q000494:pharmacology; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D013917:Thrombin / Q000378:metabolism / Q000502:physiology*
D015241:Fibrinogens, Abnormal; D006629:Hirudins; D005344:Fibrinopeptide A; D000244:Adenosine Diphosphate; D005337:Fibrin; D013917:Thrombin; D005341:Fibrinolysin; D004837:Epinephrine